Plaque Psoriasis

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

An expert nurse practitioner comments on recent advances in the treatment of plaque psoriasis, as well as the continuous need for more treatment options.

Lauren Miller, MPAS, PA-C; and Jayme Heim, MSN, FNP-BC, discuss the role of advanced practice providers (APPs) within dermatology, highlighting the medical, surgical, and cosmetic categories in the space.

This new data should be taken into account before biologics prescriptions are made for patients with conditions such as psoriasis.

A study from UCSD highlights how advances in imaging modalities and utilization could aid in the early detection of psoriatic arthritis.

This new qualitative data may be helpful both for patient-centric decision-making for clinicians as well as endpoints in future research on prurigo nodularis.

A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.

The company shared anticipation that their BLA decision for bimekizumab to treat adults with plaque psoriasis will not come before the end of this month.

In this interview segment, Jayme Heim, MRS, explored promising treatments on the horizon, hidradenitis suppurativa, and future research on teledermatology and artificial intelligence.

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

The use of this scoring system twice-per-week may help patients to better manage their mild-to-moderate atopic dermatitis.

This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.

Ashfaq Marghoob, MD, discusses his recent workshop presentation on dermoscopies for skin cancer.

The multi-center study led to several important findings, one of which being that history of biologic-use could be a factor of importance in secukinumab retention prediction.

This new analysis identified several major psoriasis risk factors, highlighting the idea that early management of such factors might help to decrease both the risk and severity of the skin disease.

The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.

This new research indicates a potentially-promising new way of addressing clinical management of prurigo nodularis.

This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.

In this interview segment, Dr. Lim further discussed findings from his team’s research into infrared radiation’s effects on the skin and the implications of these findings.

This interview featured a discussion with Dr. Lim on his team’s findings regarding the effects of infrared radiation on human skin.

Positive results from REMIX-1 and REMIX-2 on remilbrutinib could mean the beginning of a new class of chronic spontaneous urticaria therapy in about a decade.

This new data from the UK suggests possible opportunities for preventing anxiety and depression for those with eczema or psoriasis by addressing modifiable risk factors such as sleep.

This study’s findings demonstrate the necessity of risk factor identification for atopic-like dermatitis, as well as the importance of exploring alternative treatments for severe cases.

The data from this analysis indicates that for those with psoriasis, effective and long-term continuous control of the skin disease could diminish risk of CCVD risk.

The data from this new study may indicate home NBUVB treatment effectiveness and other benefits such as financial, convenience, and medical benefits.